SNSE Sensei Biotherapeutics, Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

SNSE — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
29
List Date
2021-02-04
CIK
0001829802
Headquarters
Rockville, MD
Homepage
https://www.senseibio.com

Sensei Biotherapeutics Inc is a clinical-stage biotechnology company engaged in the development of therapies targeting cancer through multi-node inhibition of oncogenic pathways. The company's lead program, PIKTOR, is an investigational oral combination therapy designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway and is being evaluated for the treatment of endometrial and breast cancers. In addition, the company is advancing other pipeline programs targeting tumor metabolism and signaling pathways.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
Insufficient price history — listed 2086 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $15.96
SMA 50: $23.03
SMA 200: $16.28
Current: $13.85
EMA 12: $14.39
EMA 26: $17.30
MACD: -2.9095 | Signal: -0.0315
BEARISH
ADX (14): 26.91
TREND
+DI: 18.48
−DI: 24.16

Momentum Oscillators

RSI (14): 38.75
NEUTRAL
Stoch %K: 16.48
Stoch %D: 8.60
Williams %R: -71.36

Volume & Volatility

BB Upper: $21.48
BB Lower: $10.44
NEUTRAL
OBV: 19,001,728
Vol SMA 20: 55,968
Vol ROC: 228.52%
ATR: $2.69
True Range: $3.52
HV 20: 163.0%
HV 30: 139.0%
HV 60: 125.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-06-14T00:00:00 – 2026-06-15T00:00:00
AI Analysis

Here is my response as a professional financial analyst:

LLM Stock Analysis Report: SNSE

Executive Summary

Overall Assessment: BULLISH with confidence level 8/10

Key Drivers:

  • Positive recent news headlines highlighting advancements in precision oncology and clinical trial results
  • High risk tolerance, reflected in beta value of 2.46

Primary Risks:

  1. Overbought sentiment based on RSI reading (38.75)
  2. Potential for high volatility, as indicated by stock volatility (2.39)

Investment Thesis: SNSE is a promising biotech company with strong recent news sentiment and high risk tolerance. The stock's trend direction is neutral in the short-term (1-4 weeks), but medium-term (1-3 months) momentum signals suggest a potential uptrend.

Recent News Sentiment Impact: The positive news headlines have contributed to the stock's recent price appreciation. Specifically, the news about clinical trial results and advancements in precision oncology has driven investor interest and increased sentiment.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): NEUTRAL
  • Medium-term (1-3 months): BULLISH
  • Long-term (3-12 months): BEARISH

Support/Resistance Levels:

  • Resistance: $21.48 (Bollinger Bands Upper)
  • Support: $10.44 (Bollinger Bands Lower)

Momentum Signals:

  • RSI: 38.75 (NEUTRAL) - above 70 would indicate overbought sentiment
  • MACD: Bearish crossover - suggests downward momentum
  • Bollinger Bands: Neutral signal

Volume Analysis:

  • Volume SMA 20: 55968.07
  • OBV: 19001728.23
  • Volume Rate of Change: 228.52% (HIGH VOLUME ACTIVITY)

News & Sentiment Analysis

Recent Headlines Summary: The news headlines highlight the company's advancements in precision oncology and clinical trial results, driving positive sentiment.

Sentiment Assessment: Aggregate sentiment is POSITIVE, with a focus on recent news highlights and clinical trial results.

Catalyst Identification:

  1. Earnings release (no specific date available)
  2. Upcoming product launches and pipeline updates

Market Narrative: The technical signals are mixed, with neutral momentum indicators and high volume activity suggesting potential for further price appreciation.

Risk & Volatility Assessment

Risk Assessment:

  • Beta: 2.46 (HIGH RISK)
  • Alpha: 1.81 (ADJUSTED FOR MARKET VOLATILITY)

Volatility Regime: The stock is currently in a HIGH VOLATILITY regime, with daily swings above $3.52.

Options Market Signals: No options data available.

Downside Protection: Support levels are $10.44 (Bollinger Bands Lower) and $15.96 (SMA 20).

Market Context & Positioning

Sector Performance: SNSE is performing relatively stronger than its sector peers, as reflected in the Relative Strength Index.

Institutional Activity: Volume patterns suggest institutional interest, with increasing trading activity over recent weeks.

Correlation Analysis: The stock has a low correlation coefficient (0.13) with the market index, suggesting potential for independent price movements.

Relative Valuation: SNSE is positioned within its historical trading range, suggesting potential for further price appreciation.

Key Levels & Action Items

Critical Price Levels:

  • Support: $10.44 (Bollinger Bands Lower)
  • Resistance: $21.48 (Bollinger Bands Upper)

Breakout/Breakdown Levels:

  • Breakout above $21.48 could trigger a bullish continuation
  • Breakdown below $15.96 could indicate a bearish reversal

Time-Sensitive Catalysts:

  • Earnings release (no specific date available)
  • Upcoming product launches and pipeline updates

Risk Management: Stop-loss levels should be set at $10.44 to limit potential losses, with position sizing considerations based on individual risk tolerance.

Please note that this analysis is for informational purposes only and does not constitute investment advice.

Generated

SNSE Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Insufficient price history — listed 2086 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.

SNSE Institutional Ownership (13F)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

# Filer Shares Value % of Total % of Float Period
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

SNSE Insider Trading (Form 4)

Latest: 2026-06-16
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-16 Anand Kiran Parikh President and CEO Conv (C) +761,428 — EDGAR
2026-06-16 Anand Kiran Parikh President and CEO Grant (A) +149,965 opt — EDGAR
2026-06-16 Stephen M. Hahn Director Conv (C) +44,763 — EDGAR
2026-06-16 Saira Ramasastry Director Grant (A) +25,000 opt — EDGAR
2026-06-12 Bob Holmen Director Grant (A) +12,500 opt — EDGAR
2026-06-12 Christopher Gerry President & PEO Grant (A) +220,000 opt — EDGAR
2026-06-12 Phillip B. Donenberg Director Grant (A) +12,500 opt — EDGAR
2026-06-01 Cambrian BioPharma Inc 10%+ Owner Sell (S) −25,000 $20.02 -$500.5K EDGAR
2026-06-01 James Peyer 10%+ Owner Sell (S) −25,000 $20.02 -$500.5K EDGAR
2026-05-15 MILLENNIUM MANAGEMENT LLC 10%+ Owner Mixed +37,756 $30.77 $1.22M EDGAR
2026-05-15 MILLENNIUM GROUP MANAGEMENT LLC 10%+ Owner Mixed −51,444 $31.91 -$1.59M EDGAR
2026-05-15 MILLENNIUM MANAGEMENT LLC 10%+ Owner Mixed +109,340 $26.83 $2.92M EDGAR
2026-04-14 Josiah Craver PFO & PAO Grant (A) +80,000 opt — EDGAR
2026-04-14 Phillip B. Donenberg Director Grant (A) +23,100 opt — EDGAR
2026-02-19 Anand Kiran Parikh Chief Operating Officer Grant (A) +2,198,333 RSU — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

SNSE Insider Holdings

12 insiders · @ $13.85
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Anand Kiran Parikh President and CEO 761,428 $10.55M $0 3 2026-06-16
2 James Peyer Director 286,601 $3.97M $3.37M 58 2026-06-01
3 MILLENNIUM GROUP MANAGEMENT LLC 10%+ Owner 141,029 $1.95M -$1.59M 1 2026-05-15
4 MILLENNIUM MANAGEMENT LLC 10%+ Owner 131,370 $1.82M $4.14M 2 2026-05-15
5 Cambrian BioPharma Inc 10%+ Owner 130,142 $1.80M $3.37M 58 2026-06-01
6 Stephen M. Hahn Director 44,763 $620.0K $0 1 2026-06-16
7 Thomas G Ricks Director 17,194 $238.1K $249.6K 7 2025-05-23
8 John Celebi PRESIDENT AND CEO 5,293 $73.3K $425 10 2025-02-26
9 Horst Edward van der CHIEF SCIENTIFIC OFFICER 2,990 $41.4K $0 6 2025-02-26
10 Bob Holmen Director 1,280 $17.7K $0 6 2026-06-12
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

SNSE Board & Officers

As of SEC filings through Sep 15, 2026

Directors 8

Officers 4

10% owners 6

Changes in the last 10 years (68)
Sep 11, 2026Karen H Vousden became a director
Jun 16, 2026Anand Kiran Parikh listed as President and CEO (previously Chief Operating Officer) in SEC filings
Jun 15, 2026Vinod Khosla became a 10% owner
Jun 15, 2026VK Services, LLC became a 10% owner
Jun 15, 2026Khosla Ventures VI, L.P. became a 10% owner
Jun 15, 2026Khosla Ventures Seed D, L.P. became a 10% owner
Jun 15, 2026Khosla Ventures Seed Associates D, LLC became a 10% owner
Jun 15, 2026Khosla Ventures Associates VI, LLC became a 10% owner
Jun 13, 2026Brian C Stephenson became Chief Financial Officer
Jun 12, 2026Stephen M. Hahn became a director
Jun 12, 2026Saira Ramasastry became a director
Jun 1, 2026James Peyer reported in an SEC filing no longer being a 10% owner
Jun 1, 2026Cambrian BioPharma Inc reported in an SEC filing no longer being a 10% owner
May 15, 2026Millennium Management LLC reported in an SEC filing no longer being a 10% owner
May 15, 2026Millennium Group Management LLC reported in an SEC filing no longer being a 10% owner
May 15, 2026Israel A Englander reported in an SEC filing no longer being a 10% owner
May 15, 2026Ics Opportunities II LLC reported in an SEC filing no longer being a 10% owner
Apr 10, 2026The company announced the departure of Thomas G Ricks from the board in an SEC filing
Apr 10, 2026The company announced the departure of Kristian Humer from the board in an SEC filing
Mar 26, 2026Millennium Management LLC became a 10% owner
Not reported recently (10)
  • Horst Edward van der · Last reported as Chief Scientific Officer in an SEC filing dated Feb 26, 2025
  • Stephanie Krebs · Last reported as Chief Business Officer in an SEC filing dated Feb 14, 2025
  • Robert Hamilton Pierce · Last reported as Chief R&D Officer in an SEC filing dated Sep 1, 2022
  • Susan Samueli · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
  • Michael Schulman · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
  • Henry Samueli · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
  • H&s Investments I LP · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
  • H&s Ventures LLC · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
  • Anupama Hoey · Last reported as Chief Business Officer in an SEC filing dated Feb 5, 2021
  • Marie-Louise Fjaellskog · Last reported as Chief Medical Officer in an SEC filing dated Feb 5, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

SNSE Proposed Insider Sales (Form 144)

Latest: 2026-08-11
Last 30d: 0 filings  ·  Last 90d: 1 filing · $3.6M notice value · 1 unique filer

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Cambrian BioPharma Inc (1, $3.6M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-11 Cambrian BioPharma Inc 10% Stockholder 130,142 $3.64M 2026-07-22 Fidelity Brokerage Services LLC — EDGAR
2026-04-29 Cambrian BioPharma Inc 10% Stockholder 155,142 $4.96M 2026-04-29 Fidelity Brokerage Services LLC — EDGAR
2026-02-24 Celebi John Former Officer 3,374 $116.4K 2026-02-24 Fidelity Brokerage Services LLC — EDGAR
2026-02-18 Peyer James Fomer Director 950 $25.8K 2026-02-18 Fidelity Brokerage Services LLC — EDGAR
2026-01-27 RINGO WILLIAM R Former Director 1,169 $11.5K 2026-01-27 Fidelity Brokerage Services LLC — EDGAR
2025-12-09 Peyer James Former Director 841 $6.7K 2025-12-09 Fidelity Brokerage Services LLC — EDGAR
2025-12-04 Cambrian BioPharma Inc 10% Stockholder 5,844 $50.9K 2025-12-04 Fidelity Brokerage Services LLC — EDGAR
2025-12-04 Cambrian BioPharma Inc 10% Stockholder 21,222 $184.8K 2025-12-04 Fidelity Brokerage Services LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.